Research
Hormonal
Intensive glycaemic control reduces microvascular complications (retinopathy, nephropathy, neuropathy) but has limited or potentially harmful effects on macrovascular outcomes and all-cause mortality.
Intensive blood sugar control helps prevent eye, kidney, and nerve damage, but it doesn't significantly prevent heart attacks and may increase the risk of low blood sugar events. Work with your doctor to find a safe blood sugar target that minimizes risks.
GoodQualifiesHIGH confidence
Initial analyses of the DCCT and UKPDS trial... demonstrated significant improvements in microvascular complications but only non-significant benefits in macrovascular disease... The results of the ACCORD trial were more concerning and found that intensive glycaemic control increased all-cause mortality by 22%...
Why this rating
Based on multiple large RCTs (DCCT, UKPDS, ADVANCE, VADT, ACCORD).
Source
Preventing diabetes complications
Sophie Templer et al. · Internal Medicine Journal · 2024
DOI 10.1111/imj.16455
narrative_reviewCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A multifactorial approach targeting glucose, blood pressure, lipids, and lifestyle simultaneously is the most effective strategy for preventing diabetes complications.Strong
- SGLT2 inhibitors and GLP-1 agonists provide significant cardiovascular and renal protection in Type 2 Diabetes, independent of their glucose-lowering effects.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →